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Background: Expression of signal transducer and activator of transcription 1 (STAT1), the mediator of
interferon (IFN) signalling, is raised in synovial tissue (ST) from patients with rheumatoid arthritis (RA).
Objectives: To determine the extent to which this pathway is activated by phosphorylation in RA synovium.
Additionally, to investigate the cellular basis of STAT1 activation in RA ST.
Methods: ST specimens from 12 patients with RA and 14 disease controls (patients with osteoarthritis and
reactive arthritis) were analysed by immunohistochemistry, using antibodies to STAT1, tyrosine
phosphorylated STAT1, and serine phosphorylated STAT1. Lysates of cultured fibroblast-like synoviocytes
stimulated with IFNb were analysed by western blotting. Phenotypic characterisation of cells expressing
STAT1 in RA ST was performed by double immunolabelling for STAT1 and CD3, CD22, CD55, or CD68.
Results: Raised levels of total STAT1 protein and both its activated tyrosine and serine phosphorylated
forms were seen in RA synovium as compared with controls. STAT1 was predominantly abundant in T and
B lymphocytes in focal inflammatory infiltrates and in fibroblast-like synoviocytes in the intimal lining layer.
Raised levels of STAT1 are sustained in cultured RA compared with OA fibroblast-like synoviocytes, and
STAT1 serine and tyrosine phosphorylation is rapidly induced upon stimulation with IFNb.
Conclusion: These results demonstrate activation of the STAT1 pathway in RA synovium by raised STAT1
protein expression and concomitantly increased tyrosine (701) and serine (727) phosphorylation. High
expression of STAT1 is intrinsic to RA fibroblast-like synoviocytes in the intimal lining layer, whereas
activation of the pathway by phosphorylation is an active process.
A
well characterised feature of rheumatoid arthritis (RA)
synovial tissue (ST) is a marked increase in cellularity.
Factors that contribute to ST hyperplasia are recruit-
ment and retention of inflammatory cells, enhanced cell
proliferation, and impaired apoptosis. Cytokines, derived
from activated synovial cells have a pivotal role in the
regulation of these processes.1
Critical in mediating virtually all cytokine driven signalling
are the members of the STAT (signal transducer and activator
of transcription) family of transcription factors, which are
involved in regulating gene expression and cellular activa-
tion, proliferation, and differentiation.2–4 Recently, we5 and
others6 demonstrated raised expression of STAT1 mRNA and
protein in the ST of patients with RA as compared with
disease controls, indicating that this pathway might be
involved in RA pathogenesis. STAT1 is essential for interferon
(IFN) signalling. IFNs are typically growth inhibitory and
promote immune recognition of target cells, and absence of
IFN/STAT1 signalling has been associated with increased
susceptibility to infection and tumour formation.7 Moreover,
STAT1 has been shown to be essential for growth restraint
imposed by IFNc and has important proapoptotic effects
through the regulation of caspases.8 9 Type I IFNs are
abundant in RA synovium,1 and limited expression of IFNc
has been shown.10 11
So far the association of STAT1 with RA only relies upon
the detection of overall STAT1 mRNA and protein in RA
synovium5 6 and observations in synovial fluid cells.12 No
information is yet available on the state of activation of
STAT1 in rheumatoid synovium. Activation of STAT1 involves
phosphorylation on tyrosine and serine residues, which are
required for the protein to exert its function. Upon binding to
the cytokine receptor, cytoplasmic STAT1 proteins are
phosphorylated on tyrosine, after which they can form
STAT1 homodimers or form complexes with other nuclear
factors, for example STAT1/STAT2/IRF9 heterotrimers, and
subsequently translocate to the nucleus to initiate transcrip-
tion. In addition, serine phosphorylation of STAT1 is required
for full transcriptional activity.13 14
In the present work we investigated the activation of
STAT1 protein in RA ST by studying its phosphorylation
compared with ST from disease controls, including patients
with osteoarthritis (OA) and reactive arthritis (ReA). In
addition, we characterised the expression and activation of
STAT1 in the various cell types in RA ST.
MATERIALS AND METHODS
Patients
ST was obtained from the actively inflamed knee joints of 26
patients, including 12 patients with RA (1987 American
College of Rheumatology (ACR) criteria15), 7 patients with
inflammatory OA (1987 criteria16), and 7 patients with ReA.
All material was obtained in the early 1990s; at that time ST
could be obtained from all patients before disease modifying
antirheumatic drug (DMARD) treatment was initiated.
Table 1 presents the clinical and demographic data of these
patients. All patients gave their informed consent and the
study protocol was approved by the medical ethics committee.
Knee joint arthroscopy and synovial biopsies
In all patients an arthroscopy was performed under local
anaesthesia using a small bore, 2.7 mm arthroscope (Storz)
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Abbreviations: ACR, American College of Rheumatology; AP, alkaline
phosphatase; BSA, bovine serum albumin; DMARD, disease modifying
antirheumatic drug; FCS, fetal calf serum; FITC, fluorescein
isothiocyanate; HPF, high power field; HRP, horseradish peroxidase;
IFM, immunofluorescence microscopy; IFN, interferon; IHC,
immunohistochemistry; IOD, integrated optical density; OA,
osteoarthritis; RA, rheumatoid arthritis; ReA, reactive arthritis; ST,
synovial tissue; STAT, signal transducer and activator of transcription
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and using an infrapatellar skin portal for macroscopic
examination of the synovium and a second suprapatellar
portal for the biopsy procedure.17 Synovial biopsy samples
were obtained from multiple regions (>6) using a 2.5 mm
grasping forceps (Storz). Tissue samples were embedded en
bloc in Tissue Tek OCT compound (Miles Diagnostics,
Elkhart, IN) and snap frozen in liquid nitrogen. The frozen
blocks were stored in liquid nitrogen until sectioned for
staining. Sections (5 mm) were cut in a cryostat and mounted
on glass slides (Star Frost adhesive slides, Knittelgla¨ser,
Braunschweig, Germany); the slides were air dried at room
temperature, carefully packed, and sealed and stored at
280 C˚ until immunohistochemical staining was performed.
Antibodies
Serial sections were stained using the following monoclonal
antibodies and diluted as indicated for immunohistochem-
istry (IHC) and immunofluorescence microscopy (IFM): anti-
STAT1, 1:160 (BD Transduction Laboratories); anti-phospho-
STAT1-tyrosine (Y701), 1:40 (Zymed Laboratories Inc, San
Francisco, CA); anti-CD3, 1:320 for IHC, 1:100 for IFM (SK4,
Becton Dickinson, San Jose, CA); anti-CD22, 1:80 for IHC,
1:50 for IFM (CLB-B-Ly, 6B11, Sanquin, Amsterdam, The
Netherlands), anti-CD55, 1:20 for IHC, 1:25 for IFM (Bric
110, Sanquin); anti-CD68, 1:320 for IHC, 1:200 for IFM (KP1,
DAKO, Glostrup, Denmark). A polyclonal antibody was used
to detect phospho-STAT1-serine (S727), 1:1000 (Upstate
Biotechnology).
Immunohistochemistry
Sections were brought to room temperature, dried, and then
fixed with acetone for 10 minutes. Endogenous peroxidase
activity was inhibited using 0.1% sodium azide and 0.3%
hydrogen peroxidase in phosphate buffered saline. Staining
was performed as described previously.18 After a primary
incubation step with the antibody of interest, bound antibody
was detected using a three step alkaline phosphatase (AP)
method for CD3, CD22, CD55, CD68. An immunoperoxidase
method was used for STAT1 and phospho-STATs. For these
antibodies, except for STAT1, staining was performed using
biotinylated tyramine (Perkin Elmer Life Sciences, Boston,
MA) for amplification.
For double IHC, sections were incubated with anti-STAT1
overnight. Horseradish peroxidase (HRP) conjugated goat-
antimouse was added for 30 minutes, followed by swine-
antigoat-HRP for 30 minutes. To prevent binding to excess
antimouse antibody, sections were blocked with 10% normal
mouse serum (Sanquin) for 15 minutes. Subsequently,
sections were incubated for 60 minutes with fluorescein
isothiocyanate (FITC) conjugated anti-CD3, -CD22, -CD55, or
-CD68, followed by rabbit-anti-FITC (DAKO) and swine-
antirabbit-AP, each for 30 minutes. HRP activity was
detected using hydrogen peroxidase as substrate and
aminoethylcarbazole as dye (Sigma, St Louis, MO). AP
activity was detected using AP substrate kit III (Vector
Laboratories, Inc, Burlingame, CA 94010). Double stained
slides were not counterstained; single stained slides were
counterstained with Mayer’s haematoxylin (Sigma) and
mounted in Kaiser’s glycerol gelatin (Merck, Darmstadt,
Germany).
Digital image analysis
Sections analysed by immunohistochemistry were coded and
assessed by digital image analysis in random order as
described previously.19 Briefly, three separate representative
regions, including the intimal lining layer and synovial
sublining, were chosen for the evaluation of each section.
Six consecutive high power fields (HPFs) from each region
were captured and digitised, resulting in a total of 18 HPFs
(surface area ,2.1 mm2). Subsequently, sections were
Table 1 Demographic and clinical data of the 12 patients with RA and the control patients, including seven patients with OA
and seven patients with ReA, who were studied for expression of STAT1 and its tyrosine and serine phosphorylated forms. All
material was collected in the early 1990s; at that time synovial tissue could be obtained from all patients before DMARD
treatment was initiated
Patient
Diagnosis
(RA/OA/ReA)
Age
(years) Sex (M/F)
Disease duration
(months) Drugs
CRP
(mg/l)
ESR
(mm/1st h)
RF
(+/2)
Erosions
(+/2)
1 RA 47 M 6 2 10 17 + 2
2 RA 80 F 4 NSAID* 47 ND + +
3 RA 76 F 8 NSAID 11 46 2 +
4 RA 73 F 4 NSAID 18 72 + +
5 RA 57 F 4 NSAID 68 81 + +
6 RA 66 F 24 NSAID 19 37 + +
7 RA 60 F 180 NSAID 53 108 + +
8 RA 58 F 192 NSAID 48 74 + +
9 RA 44 M 2 NSAID 22 33 + 2
10 RA 54 F 108 NSAID 141 93 + +
11 RA 63 M 4 NSAID 40 65 + +
12 RA 71 F 12 NSAID 49 ND + ND
13 OA 77 F 0 2 7 17 2 2
14 OA 76 F 240 NSAID 11 24 2 2
15 OA 73 F 60 2 7 18 2 2
16 OA 74 F 192 NSAID 8 14 + 2
17 OA 54 F 6 2 6 14 2 2
18 OA 67 M 8 NSAID 3 10 2 2
19 OA 77 M 12 2 ND 43 2 2
20 ReA 37 F 3 2 3 14 2 2
21 ReA 27 M 1 NSAID ND ND ND 2
22 ReA 44 M 18 2 4 9 2 2
23 ReA 33 M 11 2 3 3 2 2
24 ReA 39 F 14 NSAID 7 0 2 2
25 ReA 22 M 1 NSAID ND ND 2 2
26 ReA 67 F 4 2 23 24 2 2
RA, rheumatoid arthritis; OA, osteoarthritis; ReA, reactive arthritis; NSAID, non-steroidal anti-inflammatory drug; CRP, C reactive protein; ESR, erythrocyte
sedimentation rate; RF, rheumatoid factor; ND, not determined.
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examined using a specialised algorithm written in the
program language QUIPS operating a Qwin based (Qwin
Pro V2.4; Leica, Cambridge, UK) computer assisted, colour
video image analysis system.19 20 To quantify staining for
STAT1, STAT1-P-Tyr, and STAT1-P-Ser in the analysed
regions, integrated optical density (IOD) was calculated as
the product of staining area and intensity21 and presented as
IOD/mm2 tissue. The total cell count of the measured regions
was determined by quantification of nuclear counterstaining,
which allowed for normalisation for cellularity in all regions.
Fluorescence microscopy
Double immunofluorescence was performed on sections of
four patients with RA. The staining procedure used is a
modification of the method described previously.18 Firstly,
sections were incubated with anti-STAT1 monoclonal anti-
body, followed by incubation with tetramethylrhodamine
isothiocyanate (TRITC) conjugated goat-antimouse IgG1
antibody (Nordic, Tilburg, The Netherlands). After use of
10% normal mouse serum (Sanquin) as blocking serum,
incubation with FITC labelled anti-CD3, -CD22, -CD55, or
-CD68 was performed on serial sections. Sections were
embedded in mounting medium (Vectashield, Vector Labs
Inc) and analysed by two independent assessors (PVK and
TJS). During the analysis, all cells that were double positive
for STAT1 and the respective CD marker were counted and
given as a percentage of the absolute number of either CD3+,
CD22+, CD55+, or CD68+ cells in the biopsy specimens.
Cell culture and stimulation
Fibroblast-like synoviocytes were obtained from synovial
biopsy samples of patients with RA who fulfilled the criteria
of the ACR15 and patients with OA (1987 criteria16). After
enzymatic digestion, fibroblast-like synoviocytes were grown
in culture flasks in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum (FCS), and cells
were routinely split. Experiments were performed using third
to sixth passage fibroblast-like synoviocytes. At this time,
,2% contaminating lymphocytes, NK cells, or macrophages
were present. The day before an experiment, cells were
replated in medium containing 0.5% FCS. Stimulation was
performed for 30 minutes in six-well dishes using recombi-
nant human IFNb (Sanquin) at a final concentration of 250
U/ml. Cell extracts were prepared in ice cold RIPA buffer
(20 mM Tris; 150 nM NaCl; 1% sodium deoxycholic acid; 1%
NP-40; 0.1% sodium dodecyl sulphate; 50 mM NaF; 250 mM
Na3VO4; 10 mM Na2PHO4; 1 pill/50 ml of Complete (Roche)
protein inhibitor) and kept on ice on a shaking platform for
30 minutes. After centrifugation at 4000 rpm for 10 minutes,
supernatants were transferred to a fresh tube and frozen at
220 C˚ until further use.
Western blot analysis
Cell lysates of fibroblast-like synoviocytes were corrected for
total protein content (35 mg total protein per lane) and
fractionated on 7.5% sodium dodecyl sulphate-polyacryla-
mide gels and transferred to nitrocellulose membranes.
Membranes were blocked in Tris buffered saline-Tween/3%
bovine serum albumin (BSA) for 1 hour and then incu-
bated with the antibodies described above that were dir-
ected against STAT1, phospho-STAT1-tyrosine (Y701), or
phospho-STAT1-serine(S727) at a dilution of 1:500 in
Tris buffered saline-Tween/1% BSA. Enhanced chemilumine-
scence was used for detection.
Statistical analysis
The Mann-Whitney two sample test was used for comparison
of RA ST with control ST.
RESULTS
Activation of the STAT1 pathway in RA synovium
To obtain insight into the extent of activation of the STAT1
pathway in RA synovium, immunohistochemical studies
were performed on the ST of 12 patients with RA and 14
disease controls, including 7 patients with OA and 7 with
ReA (table 1). Only patients who had not yet been treated
with DMARDs were included in the study, and the RA patient
group consisted of patients with both early and longstanding
RA. Serial sections were stained for STAT1 and both its
phosphorylated forms, phospho-STAT1(Y701) and phospho-
STAT1(S727). STAT1 expression and phosphorylation was
predominantly abundant in the intimal lining layer and in
focal inflammatory infiltrates in the synovial sublining
(fig 1A).
To make a quantitative comparison between the patients
with RA and the control group, expression was quantified by
digital image analysis.19 20 Comparison of RA ST with ST of
disease controls showed that STAT1 protein expression was
raised in RA ST (expressed as mean (SD) IOD per mm2 of
tissue, 209 (214) v 24 (29) in disease controls, p = 0.0097,
data not shown), which is consistent with our previously
reported results.5 Normalisation to the total number of cells
present in the sections shows that the difference is still highly
significant (p = 0.014), indicating that this effect could not
merely be explained by differences in leucocyte infiltration.
In addition, we found that STAT1 phosphorylation on
tyrosine was significantly increased in RA ST as compared
with controls (p = 0.017) as well as phosphorylation on
serine (p = 0.029) (fig 1B). Calculation of the ratio of
phosphorylated STAT1 to total STAT1 present for each
patient showed no significant differences between patients
with RA and disease controls (p = 0.70 and p = 0.52 for
STAT1-P-Tyr/STAT1 and STAT1-P-Ser/STAT1, respectively),
which suggests that activation by phosphorylation may
increase concomitantly with STAT1 expression.
STAT1 is differentially expressed in RA synovial tissue
To evaluate specifically which cells in the different synovial
compartments express STAT1, immunohistochemical double
labelling was performed on the ST of four patients with RA
using antibodies to detect T cells (anti-CD3), B cells (anti-
CD22), fibroblast-like synoviocytes (anti-CD55), and macro-
phages (anti-CD68).
In the synovial sublining, STAT1 was mainly localised in
both B and T lymphocytes (figs 2A and B). Focal inflamma-
tory infiltrates of CD22+ B cells were found that exhibited
strongly positive staining for STAT1 (fig 2A). High STAT1
expression was also seen in CD3+ T lymphocytic aggregates.
Interestingly, in one patient both STAT1 positive T lympho-
cytic aggregates and T lymphocytic aggregates that were
entirely negative for STAT1 were seen (fig 2B). CD68+ macro-
phages were abundant around lymphocyte clusters and in the
intimal lining layer. Regardless of their position in the tissue,
staining for STAT1 was relatively limited in these cells (fig 2D).
In contrast, CD55+ fibroblast-like synoviocytes in the
intimal lining layer stained strongly positive for STAT1
(fig 2C).
To make a quantitative assessment of the percentage of
STAT1+cells in these synovial cell populations, double
immunofluorescence was performed (fig 3A) on the ST of
four patients with RA who were not included in the previous
analysis. The results confirmed the observation that STAT1 is
expressed by B lymphocytes (fig 3B; mean (SD) STAT1+ cells
of total CD22+ cells = 45 (5)%), T lymphocytes (54 (8)%),
and the majority of fibroblast-like synoviocytes (87 (9)%).
Only a limited number of macrophages (18 (15)%) were
found to be STAT1+. Taken together, these results indicate
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Figure 1 Increased STAT1 phosphorylation on tyrosine and serine in RA ST as compared with controls. Serial ST sections from 12 patients with RA
and 14 controls were stained for STAT1-phospho-tyrosine and STAT1-phospho-serine using aminoethylcarbazole as dye (A) representative sections
are shown. Counterstaining was performed using Mayer’s haematoxylin. (Original magnification 6400.) Sections were analysed using computer
assisted digital image analysis (B). Results are shown as means, errors bars indicate SD; on the y axis the mean IOD per mm2 of tissue (see ‘‘Materials
and methods’’) is shown.
Figure 2 Immunohistochemical double labelling of the ST of four patients with RA (table 1; patients Nos 4, 5, 7, and 13; representative sections are
shown) for STAT1 and CD22+ B cells (A), CD3+ T cells (B), CD55+ fibroblast-like synoviocytes (C), or CD68+ macrophages (D). STAT1 was detected
using aminoethylcarbazole as dye (red) and CD molecules were detected using AP substrate (blue); no counterstaining was performed (see ‘‘Materials
and methods’’). (Original magnification6400.)
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that the abundance of STAT1 in the intimal lining layer is
predominantly due to expression by fibroblast-like synoviocytes.
STAT1 expression and activation in fibroblast-like
synoviocytes
To validate our in vivo observations, we assessed the
expression of STAT1 in RA and OA fibroblast-like synovio-
cytes by immunoblot analysis of lysates of cultured cells.
These studies disclosed higher expression of STAT1 in RA
fibroblast-like synoviocytes than in OA synoviocytes (fig 4),
which is consistent with our in vivo observations in whole ST.
Interestingly, although expression of STAT1 was sustained in
vitro, tyrosine phosphorylation was absent and only low basal
levels of serine phosphorylation were found in cultured
fibroblast-like synoviocytes from both patients with RA and
OA. Stimulation with IFNb rapidly induced both tyrosine and
serine phosphorylation. These results show that whereas
raised expression of STAT1 is a stable, instrinsic feature of RA
fibroblast-like synoviocytes, activation of STAT1 by phos-
phorylation is not sustained in culture. Induction of
phosphorylation on both tyrosine and serine residues appears
to be an active process, which can be induced by IFNb, a
cytokine that is abundantly expressed in RA synovium.
DISCUSSION
The prime aim of the present study was to extend our
understanding of the expression and activation of STAT1 in
RA. Previously, we5 and others6 reported that STAT1
expression is raised in RA synovium as compared with
controls, and STAT1 activation has been shown in rheuma-
toid synovial fluid cells.12 In the present work we provide
evidence for activation of the STAT1 pathway in RA
synovium and define the cell types that express STAT1.
Raised expression of STAT1 appears to be intrinsic to RA
fibroblast-like synoviocytes, whereas activation by phosphor-
ylation is an active process.
Regulation of signalling through the Jak-STAT pathway is
complex and occurs at several levels within the cell. Up
regulation of STAT1 mRNA and protein expression in
response to stimulation with IFNs have been described
previously.6 22 Key post-translational modifications include
tyrosine and serine phosphorylation, which are required for
dimerisation and full transcriptional activity of STATs.13 14
Our results demonstrate that activation of STAT1 in the RA
inflamed joint is not only reflected by increased expression of
STAT1 but also by increased phosphorylation on both
tyrosine (701) and serine (727) residues. The fact that
Figure 3 Double immunofluorescence
was performed on the ST of four
patients with RA (table 1; patients Nos
1, 2, 3, and 10). (A) STAT1
(tetramethylrhodamine) and CD22+ B
cells, CD3+ T cells, CD55+ fibroblast-
like synoviocytes, or CD68+
macrophages (fluorescein). No
counterstaining was performed.
(Original magnification6400.) (B)
Percentage STAT1+ cells of,
respectively, total CD22+, CD3+,
CD55+, or CD68+ cells. Bars represent
mean (SD) (n = 4).
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STAT1 activation is less pronounced in patients with OA and
ReA may reflect the differential expression of IFNb and IFNc
between diseases. These findings are in line with our
microarray results, which demonstrated an increased expres-
sion of IFN-induced genes in RA STs that display up
regulation of STAT1 mRNA.5 The observation that ratios of
phosphorylated STAT1 to total STAT1 for each patient are
comparable in patients with RA and controls suggests that up
regulation of STAT1 protein expression and its activation by
phosphorylation are concomitant events. Whether this is
really true, however, can only be determined if extensive
studies at the single cell level are performed.
In accordance with our microarray gene profiling
results,5 23 we observed considerable variation in STAT1
expression and activation among patients with RA and
controls. In the patient group studied patients with both early
and longstanding RA were included, and no correlations
between STAT1 activation and the duration of disease or
other clinical variables (table 1) were found. This, however,
may be due to the relatively small number of patients
studied. We investigated the expression profile of STAT1 in
the different synovial compartments in patients with RA by
using two different double labelling techniques. In the
synovial sublining we detected increased STAT1 protein
expression in focal inflammatory infiltrates of both B and T
lymphocytic origins. Interestingly, in one patient we detected
a STAT1 positive perivascular T lymphocytic aggregate (fig 3A,
second panel). Although the majority of lymphocytic
infiltrates in RA were STAT1 positive, in some aggregates
STAT1 expression was entirely absent. This can be seen in
fig 2, where a STAT1 positive T lymphocyte aggregate and an
adjacent STAT1 negative aggregate are shown (fig 2B). These
findings suggest that STAT1 is differentially expressed in
synovial lymphocytes, which may reflect the state of
activation and cellular differentiation of these cells.
STAT1 expression was also abundant in the intimal lining
layer. The vast majority of fibroblast-like synoviocytes in the
intimal lining layer expressed high levels of STAT1, whereas
only limited expression of STAT1 was found in macrophages,
regardless of their position in either intimal lining layer or
synovial sublining. This is particularly interesting in light of
the recent report by Hu et al,6 who demonstrated the
existence of a delicate regulatory system for STAT1 in IFNc
signalling. They showed that exposure of macrophages to
subthreshold concentrations of IFNc sensitises these cells to
subsequent IFNc stimulation, which results in increased
STAT1 expression. To find supporting evidence for the
occurrence of this mechanism in vivo, they stated that
STAT1 protein expression is increased in RA synovium,
particularly in the intimal lining layer. In their rationale they
implied that this might be due to intimal macrophages
displaying increased STAT1 expression as a result of the IFNc
responses that lead to tissue abnormality in RA. However, our
results demonstrate that the abundance of STAT1 in the
intimal lining predominantly results from STAT1 expression
by fibroblast-like synoviocytes.
It has been suggested that RA fibroblast-like synoviocytes
not only respond to stimulation by proinflammatory cyto-
kines but also show intrinsic molecular changes that are
maintained in the absence of external stimuli.24 25 Here we
demonstrated that increased expression of STAT1 in RA
compared with OA fibroblast-like synoviocytes is sustained in
culture. On the other hand, phosphorylation of STAT1 is
almost completely lost in vitro, indicating that this is an
active process that can be induced by cytokines in RA
synovium. This notion is supported by the observation that
STAT1 phosphorylation in fibroblast-like synoviocytes is
rapidly restored upon stimulation with the type I interferon
IFNb. IFNb is produced by fibroblast-like synoviocytes and
abundant in synovium. Therefore, conceivably, this mechan-
ism of STAT1 activation takes place in vivo in fibroblast-like
synoviocytes. Type I interferons are believed to have
immunosuppressive functions, including antiangiogenic
effects. On the other hand, IFNb produced by fibroblast-like
synoviocytes can act as a survival factor for T cells in the
rheumatoid joint.26 It is interesting to note that stimulation
with IFNc also induced STAT1 phosphorylation in fibroblast-
like synoviocytes (data not shown). Because IFNc expression
is absent in the synovial lining this mechanism of STAT1
activation may rather be of importance in other synovial cell
types.
Evidence for the importance of the Jak-STAT pathway in
RA pathogenesis is accumulating, and has so far mainly been
focused on the role of STAT3 and its growth promoting role.
Accordingly, Shouda et al demonstrated that blockade of
STAT3 by overexpression of SOCS3, a STAT3-induced
inhibitor of Jak-STAT signalling, suppressed experimental
arthritis.27 In contrast, an important effector function of
STAT1 is its growth inhibitory effect. STAT1 is required for
the growth restraint imposed by IFNa and IFNc28 and the
promotion of apoptosis.8 29 30 Krause et al showed that the
proapoptotic action of STAT1 is antagonised by STAT3,31
which appears to be essential for RA synoviocyte survival.
This is in line with the notion that STAT1 and STAT3 can
serve as a tumour suppressor and a tumour promoter,
respectively.7 Because our data demonstrate that besides the
STAT3 signalling pathway the STAT1 pathway also is
activated in fibroblast-like synoviocytes, it is tempting to
speculate that the proapoptotic signals delivered by STAT1 in
these cells in vivo are not strong enough to effectively
counteract the STAT3 derived survival signals.
STAT1 may have a role as transcriptional activator as a
STAT1 homodimer or as a constituent of a complex involving
other factors, for example the STAT1/STAT2/IRF9 hetero-
trimer. For the future it is challenging to know in which form
STAT1 exerts its biological effects in ST, and what part
activation of STAT1 plays in the fate of infiltrating
lymphocytes. A better understanding of the balance of
signals delivered through the different STAT pathways by
dissecting the individual pathways and evaluating their
contributions to either cell survival or growth arrest may
Figure 4 STAT1 expression is raised in RA compared with OA
fibroblast-like synoviocytes (top panel) and STAT1 tyrosine and serine
phosphorylation are induced by stimulation with IFNb (second and third
panels). Fourth passage RA and OA synoviocytes were treated with IFNb
(250 U/ml). Cell extracts were prepared 30 minutes after cytokine
stimulation, corrected for total protein content, and analysed by
immunoblotting.
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contribute to elucidating the disease mechanisms that are at
play in RA.
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